Home / News / Certara Announces Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Certara Announces Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

PRINCETON, N.J.— September 13, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it closed its public offering of 23,000,000 shares of common stock at $31.00 per share. The closing includes 3,000,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. Certara sold 4,500,000 shares of its common stock, and certain selling stockholders sold 18,500,000 shares of common stock in the offering. The gross proceeds to Certara from the offering were approximately $139.5 million, before deducting the underwriting discount and offering expenses. Certara intends to use the net proceeds from shares it is selling in the offering for general corporate purposes, including acquisitions. Certara did not receive any proceeds from the sale of shares in the offering by the selling stockholders.

The offering was made through an underwriting group led by Jefferies, Morgan Stanley and BofA Securities, who acted as lead joint book-running managers, and William Blair, Credit Suisse, Barclays and Capital One Securities, who acted as joint book-running managers.

A registration statement on Form S-1, including a prospectus, relating to these securities was declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 547-6340 or by email at Prospectus_Department@jefferies.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; or BofA Securities, Inc., NC1-004-03-43, Attention: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, NC 29255 or by email at dg.prospectus_requests@bofa.com.


About Certara

Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,650+ global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Contacts

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contacts:

Daniel Yunger
Kekst CNC
daniel.yunger@kekstcnc.com

Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com

Media Contact:

Back to top